VORVor Biopharma Inc.同业对比
Vor Biopharma Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VOR本股 | $1.3B#8 | 0.1x#1 | — | — | — | -495.3%#15 | — | — | — | — | -29.8%#14 | — |
| VIR | $1.8B#1 | — | 1.8x#1 | 25.8x#6 | -7.6%#9 | 16.1%#5 | -699.2%#6 | -44.6%#7 | — | — | 117.7%#5 | — |
| RXRX | $1.7B#2 | — | 1.9x#2 | 23.2x#5 | 26.9%#6 | -39.1%#11 | -867.9%#7 | -70.5%#10 | -175.2%#3 | — | -32.3%#15 | — |
| TSHA | $1.7B#3 | — | 4.3x#8 | 169.0x#8 | 17.3%#7 | -22.1%#8 | -1130.6%#8 | -28.1%#3 | — | — | 68.2%#9 | — |
| INBX | $1.6B#4 | — | — | 1205.0x#9 | 550.0%#2 | -108.3%#13 | -10386.5%#10 | — | — | — | 292.0%#1 | — |
| NVAX | $1.5B#5 | — | — | 1.4x#1 | 64.7%#4 | 334.8%#1 | 40.3%#1 | — | — | — | 14.4%#11 | — |
| MAZE | $1.3B#6 | — | 3.0x#6 | 8.0x#2 | — | -351.0%#14 | -85.3%#3 | -28.9%#4 | -49.4%#2 | — | 4.2%#12 | — |
| CGEM | $1.3B#7 | — | 3.2x#7 | — | -100.0%#11 | -31.2%#10 | — | -53.8%#9 | — | — | 224.1%#2 | — |
| MGTX | $1.2B#10 | 14.7x#2 | — | 15.1x#4 | 144.6%#3 | 22.7%#4 | -130.2%#4 | — | — | — | 74.1%#8 | — |
| GLUE | $1.1B#11 | — | 2.3x#3 | 9.0x#3 | 63.5%#5 | 46.9%#2 | -43.8%#2 | -7.9%#2 | — | — | 87.8%#7 | — |
| REPL | $1.2B#9 | — | 11.6x#11 | — | — | -26.9%#9 | — | -297.1%#12 | -7270.9%#4 | — | 130.1%#3 | — |
| ODTX | $1.1B#12 | — | 2.5x#5 | — | — | — | — | 0.0%#1 | — | — | — | — |
| SANA | $949M#13 | — | 6.1x#9 | — | — | 8.5%#7 | — | -158.0%#11 | — | — | -1.9%#13 | — |
| SLDB | $896M#14 | — | 2.4x#4 | 110.7x#7 | -40.6%#10 | -39.8%#12 | -2214.1%#9 | -46.6%#8 | — | — | 52.1%#10 | — |
| CADL | $852M#15 | — | 6.8x#10 | 6813.2x#10 | 0.0%#8 | 30.8%#3 | -38612.8%#11 | -30.3%#5 | — | — | 129.7%#4 | — |
| FDMT | — | — | — | — | 230194.6%#1 | 12.9%#6 | -187.2%#5 | -34.4%#6 | -44.7%#1 | — | 100.4%#6 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议